Objective:To evaluate the efficacy and tolerability of lubiprostone (Amitiza) for constipation in Parkinson disease (PD) in a double-blind, randomized, controlled study.
Methods:Patients with PD and clinically meaningful constipation (constipation rating scale score10 [range: 028]) were recruited from 2 academic movement disorder centers to partic-ipate in the study. After enrollment, patients were initially followed for 2 weeks and then were randomly assigned 1:1 to lubiprostone, and the dosewas titrated up to 48g/day. They returned 4 weeks later for a final assessment. Data included stool diaries and global impressions (copri-mary endpoints), demographics, Unified Parkinson’s Disease Rating Scale scores, constipation scale scores, visual analog scale (VAS) scores, a stool diary, and adverse events.